Risk factors, mortality, and predictors of survival in COVID-19-associated pulmonary mucormycosis : a multicentre retrospective study from India
Copyright © 2023 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved..
OBJECTIVES: To compare COVID-19-associated pulmonary mucormycosis (CAPM) with COVID-19-associated rhino-orbital mucormycosis (CAROM), ascertain factors associated with CAPM among patients with COVID-19, and identify factors associated with 12-week mortality in CAPM.
METHODS: We performed a retrospective multicentre cohort study. All study participants had COVID-19. We enrolled CAPM, CAROM, and COVID-19 subjects without mucormycosis (controls; age-matched). We collected information on demography, predisposing factors, and details of COVID-19 illness. Univariable analysis was used to compare CAPM and CAROM. We used multivariable logistic regression to evaluate factors associated with CAPM (with hypoxemia during COVID-19 as the primary exposure) and at 12-week mortality.
RESULTS: We included 1724 cases (CAPM [n = 122], CAROM [n = 1602]) and 3911 controls. Male sex, renal transplantation, multimorbidity, neutrophil-lymphocyte ratio, intensive care admission, and cumulative glucocorticoid dose for COVID-19 were significantly higher in CAPM than in CAROM. On multivariable analysis, COVID-19-related hypoxemia (aOR, 2.384; 95% CI, 1.209-4.700), male sex, rural residence, diabetes mellitus, serum C-reactive protein, glucocorticoid, and zinc use during COVID-19 were independently associated with CAPM. CAPM reported a higher 12-week mortality than CAROM (56 of the 107 [52.3%] vs. 413 of the 1356 [30.5%]; p = 0.0001). Hypoxemia during COVID-19 (aOR [95% CI], 3.70 [1.34-10.25]) and Aspergillus co-infection (aOR [95% CI], 5.40 [1.23-23.64]) were independently associated with mortality in CAPM, whereas surgery was associated with better survival.
DISCUSSION: CAPM is a distinct entity with a higher mortality than CAROM. Hypoxemia during COVID-19 illness is associated with CAPM. COVID-19 hypoxemia and Aspergillus co-infection were associated with higher mortality in CAPM.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases - 30(2024), 3 vom: 15. Feb., Seite 368-374 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Aspergillus |
|---|
| Anmerkungen: |
Date Completed 20.02.2024 Date Revised 20.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cmi.2023.12.006 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365721816 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365721816 | ||
| 003 | DE-627 | ||
| 005 | 20240220232215.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cmi.2023.12.006 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1300.xml |
| 035 | |a (DE-627)NLM365721816 | ||
| 035 | |a (NLM)38081413 | ||
| 035 | |a (PII)S1198-743X(23)00596-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Muthu, Valliappan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Risk factors, mortality, and predictors of survival in COVID-19-associated pulmonary mucormycosis |b a multicentre retrospective study from India |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.02.2024 | ||
| 500 | |a Date Revised 20.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved. | ||
| 520 | |a OBJECTIVES: To compare COVID-19-associated pulmonary mucormycosis (CAPM) with COVID-19-associated rhino-orbital mucormycosis (CAROM), ascertain factors associated with CAPM among patients with COVID-19, and identify factors associated with 12-week mortality in CAPM | ||
| 520 | |a METHODS: We performed a retrospective multicentre cohort study. All study participants had COVID-19. We enrolled CAPM, CAROM, and COVID-19 subjects without mucormycosis (controls; age-matched). We collected information on demography, predisposing factors, and details of COVID-19 illness. Univariable analysis was used to compare CAPM and CAROM. We used multivariable logistic regression to evaluate factors associated with CAPM (with hypoxemia during COVID-19 as the primary exposure) and at 12-week mortality | ||
| 520 | |a RESULTS: We included 1724 cases (CAPM [n = 122], CAROM [n = 1602]) and 3911 controls. Male sex, renal transplantation, multimorbidity, neutrophil-lymphocyte ratio, intensive care admission, and cumulative glucocorticoid dose for COVID-19 were significantly higher in CAPM than in CAROM. On multivariable analysis, COVID-19-related hypoxemia (aOR, 2.384; 95% CI, 1.209-4.700), male sex, rural residence, diabetes mellitus, serum C-reactive protein, glucocorticoid, and zinc use during COVID-19 were independently associated with CAPM. CAPM reported a higher 12-week mortality than CAROM (56 of the 107 [52.3%] vs. 413 of the 1356 [30.5%]; p = 0.0001). Hypoxemia during COVID-19 (aOR [95% CI], 3.70 [1.34-10.25]) and Aspergillus co-infection (aOR [95% CI], 5.40 [1.23-23.64]) were independently associated with mortality in CAPM, whereas surgery was associated with better survival | ||
| 520 | |a DISCUSSION: CAPM is a distinct entity with a higher mortality than CAROM. Hypoxemia during COVID-19 illness is associated with CAPM. COVID-19 hypoxemia and Aspergillus co-infection were associated with higher mortality in CAPM | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Aspergillus | |
| 650 | 4 | |a CAPA | |
| 650 | 4 | |a Fungal pneumonia | |
| 650 | 4 | |a Invasive fungal infection | |
| 650 | 4 | |a Invasive mould infection | |
| 650 | 4 | |a Rhizopus | |
| 650 | 4 | |a Steroids | |
| 650 | 7 | |a Glucocorticoids |2 NLM | |
| 700 | 1 | |a Agarwal, Ritesh |e verfasserin |4 aut | |
| 700 | 1 | |a Rudramurthy, Shivaprakash Mandya |e verfasserin |4 aut | |
| 700 | 1 | |a Thangaraju, Deepak |e verfasserin |4 aut | |
| 700 | 1 | |a Shevkani, Manoj Radhakishan |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Atul K |e verfasserin |4 aut | |
| 700 | 1 | |a Shastri, Prakash Srinivas |e verfasserin |4 aut | |
| 700 | 1 | |a Tayade, Ashwini |e verfasserin |4 aut | |
| 700 | 1 | |a Bhandari, Sudhir |e verfasserin |4 aut | |
| 700 | 1 | |a Gella, Vishwanath |e verfasserin |4 aut | |
| 700 | 1 | |a Savio, Jayanthi |e verfasserin |4 aut | |
| 700 | 1 | |a Madan, Surabhi |e verfasserin |4 aut | |
| 700 | 1 | |a Hallur, Vinaykumar |e verfasserin |4 aut | |
| 700 | 1 | |a Maturu, Venkata Nagarjuna |e verfasserin |4 aut | |
| 700 | 1 | |a Srinivasan, Arjun |e verfasserin |4 aut | |
| 700 | 1 | |a Sethuraman, Nandini |e verfasserin |4 aut | |
| 700 | 1 | |a Singh Sibia, Raminder Pal |e verfasserin |4 aut | |
| 700 | 1 | |a Pujari, Sanjay |e verfasserin |4 aut | |
| 700 | 1 | |a Mehta, Ravindra |e verfasserin |4 aut | |
| 700 | 1 | |a Singhal, Tanu |e verfasserin |4 aut | |
| 700 | 1 | |a Saxena, Puneet |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Varsha |e verfasserin |4 aut | |
| 700 | 1 | |a Nagvekar, Vasant |e verfasserin |4 aut | |
| 700 | 1 | |a Prayag, Parikshit |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Dharmesh |e verfasserin |4 aut | |
| 700 | 1 | |a Xess, Immaculata |e verfasserin |4 aut | |
| 700 | 1 | |a Savaj, Pratik |e verfasserin |4 aut | |
| 700 | 1 | |a Sehgal, Inderpaul Singh |e verfasserin |4 aut | |
| 700 | 1 | |a Panda, Naresh |e verfasserin |4 aut | |
| 700 | 1 | |a Rajagopal, Gayathri Devi |e verfasserin |4 aut | |
| 700 | 1 | |a Parwani, Riya Sandeep |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Kamlesh |e verfasserin |4 aut | |
| 700 | 1 | |a Deshmukh, Anuradha |e verfasserin |4 aut | |
| 700 | 1 | |a Vyas, Aruna |e verfasserin |4 aut | |
| 700 | 1 | |a Gandra, Raghava Rao |e verfasserin |4 aut | |
| 700 | 1 | |a Sistla, Srinivas Kishore |e verfasserin |4 aut | |
| 700 | 1 | |a Padaki, Priyadarshini A |e verfasserin |4 aut | |
| 700 | 1 | |a Ramar, Dharshni |e verfasserin |4 aut | |
| 700 | 1 | |a Sarkar, Saurav |e verfasserin |4 aut | |
| 700 | 1 | |a Rachagulla, Bharani |e verfasserin |4 aut | |
| 700 | 1 | |a Vallandaramam, Pattabhiraman |e verfasserin |4 aut | |
| 700 | 1 | |a Premachandran, Krishna Prabha |e verfasserin |4 aut | |
| 700 | 1 | |a Pawar, Sunil |e verfasserin |4 aut | |
| 700 | 1 | |a Gugale, Piyush |e verfasserin |4 aut | |
| 700 | 1 | |a Hosamani, Pradeep |e verfasserin |4 aut | |
| 700 | 1 | |a Dutt, Sunil Narayan |e verfasserin |4 aut | |
| 700 | 1 | |a Nair, Satish |e verfasserin |4 aut | |
| 700 | 1 | |a Kalpakkam, Hariprasad |e verfasserin |4 aut | |
| 700 | 1 | |a Badhwar, Sanjiv |e verfasserin |4 aut | |
| 700 | 1 | |a Kompella, Kiran Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Singla, Nidhi |e verfasserin |4 aut | |
| 700 | 1 | |a Navlakhe, Milind |e verfasserin |4 aut | |
| 700 | 1 | |a Prayag, Amrita |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Gagandeep |e verfasserin |4 aut | |
| 700 | 1 | |a Dhakecha, Poorvesh |e verfasserin |4 aut | |
| 700 | 1 | |a Chakrabarti, Arunaloke |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases |d 1995 |g 30(2024), 3 vom: 15. Feb., Seite 368-374 |w (DE-627)NLM094580014 |x 1469-0691 |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2024 |g number:3 |g day:15 |g month:02 |g pages:368-374 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cmi.2023.12.006 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2024 |e 3 |b 15 |c 02 |h 368-374 | ||